PTC/SB/08a (08-03)
Approved for use through 07/31/2006, OMB 0651-0301
U.S. Patient and Trademank Office, U.S. DEPARTMENT OF COMMERCE
and to a collection of information unless of contains a valid OMB control number.

	Application Number		10797639	
	Filing Date		2004-03-09	
INFORMATION DISCLOSURE	First Named Inventor Uwe DeWinter		DeWinter	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		3727	
(Not for Submission ander 57 Grit 1997)	Examiner Name	Shawn M. Braden		
	Attorney Docket Numb	er	8966.23	

				U.S.	PATENTS			Remove		
Examiner Cite Initial* No Patent Number Kind Code		Kind Code ¹	Issue Date Name of Patentee or Applicant		Pages,Columns,Lines where Relevant Passages or Relev Figures Appear					
	1	6279767		2001-08-18	Yoon					
	2	6331022		2001-12-18	Liroff	}-				
If you wisi	h to a	dd additional U.S. Pate	nt citatio	n information p	lease click the	Add button.		Add		_
			U.S.P	ATENT APPLI	CATION PUB	LICATIONS		Remove		_
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Par of cited Doc	tentee or Applicant ument	Pages, Columns, Lines where Relevant Passages or Refigures Appear			
If you wis	1 h to a	dd additional U.S. Pub		plication citatio		•	d buttor	Add		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	y Kind	Publication	Name of Patente Applicant of cited Document	e or	where Rel	or Relevant	76
	1	DE9316004			1993-10-20	Autohaus Arscholl	Gmit			
	2	JP09207648			1997-12-08	Riyoushiyoku.KK T	oupure			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

pplication Number		10797639		
iling Date		2004-03-09		
rst Named Inventor Uwe D		DeWinter		
rt Unit		3727		
xaminer Name Shaw		n M. Braden		
Homou Docket Number		8966 23		

If you wisl	h to a	dd add	titional Foreign Patent Document citation information please click the Add butto	on Add			
			NON-PATENT LITERATURE DOCUMENTS	Remove			
Examinor Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, sorial, symposium, catalog, etc), date, pages(s), volume-issue numbor(s), publisher, city and/or country where published.					Τs		
	1						
If you wis	h to a	dd add	ditional non-patent literature document citation information please click the Add	button Add			
			EXAMINER SIGNATURE				
Examiner	Examiner Signature Date Considered						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

F

1 See Kinz Code of USPTO Platent Documents at year, <u>USPTO CODE</u> or MEPP 910.4. ² Either office that issued the document, by the ho-lefter code (WPO Standard 513.). ² The Japanese parted converset, the relication to be year of the respirat of the Either or Merit 10 to Either of the Standard 513.0 ² Either office that the Standard 513.0 ² Either office that the Standard 51 to Standard 5

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 GFR 1.99)

Application Number		10797639
Filing Date		2004-03-09
First Named Inventor U		DeWinter
Art Unit		3727
Examiner Name Shaw		n M. Braden
Attorney Docket Number		8966.23

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication
from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 179(c).

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Na.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Michael F. Krieger/	Date (YYYY-MM-DD)	
Name/Print	Michael F Krieger	Registration Number	35.232

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR.

1.14. This collection is estimated to take if hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. operatment of Comments of Configuration of Configuration of Comments of Configuration of C

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.